A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2012
At a glance
- Drugs PG 11047 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Progen Pharmaceuticals Limited
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2012 Actual end date (August 2009) added as reported by ClinicalTrials.gov.
- 22 Jan 2012 Additional lead trial investigator and actual patient no 46 identified as reported by ClinicalTrials.gov.